Key result
Ezetimibe combined with a statin effectively lowers LDL-C and may improve renal function, insulin resistance, and inflammatory markers in patients with diabetes.
Why the study?
Does ezetimibe provide pleiotropic benefits beyond cholesterol lowering in patients with diabetes?
Does ezetimibe provide pleiotropic benefits beyond cholesterol lowering in patients with diabetes?
Answers are grounded in this paper and cite their sources.
Ezetimibe may offer pleiotropic benefits such as improved renal function and insulin resistance in addition to effective LDL-C lowering in patients with diabetes.
Ezetimibe, an inhibitor of cholesterol intestinal absorption, is a lipid lowering agent with potential pleiotropic actions. Ezetimibe in combination with a statin is effective in decreasing low density lipoprotein cholesterol(LDL-C), lowering triglyceride and raising high density lipoprotein cholesterol levels. Ezetimibe plus statin achieve LDL-C targets in a greater proportion of patients than statin monotherapy. Ezetimibe also seems to improve renal function, insulin resistance and inflammatory markers. These actions are useful in patients with diabetes. Ezetimibe is a well-tolerated and effective (in terms of achieving LDL-C targets) option inpatients with hyperlipidemia with or without diabetes. This editorial will discuss several properties of ezetimibe, with special reference to diabetes.
No takes yet. Share an insight, caveat, or question.
Sarigianni et al. (2010) conducted an editorial in Diabetes and hyperlipidemia. Ezetimibe vs. Statin monotherapy was evaluated. Ezetimibe combined with a statin effectively lowers LDL-C and may improve renal function, insulin resistance, and inflammatory markers in patients with diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: